Research from Health Research Inc. Provides New Study Findings on Pancreatic Cancer (Anakinra-Loaded Sphingomyelin Nanosystems Modulate In Vitro IL-1-Dependent Pro-Tumor Inflammation in Pancreatic Cancer).

A new study on pancreatic cancer has found that the tumor microenvironment in pancreatic cancer secretes cytokines, including interleukin (IL)-1, which exerts immunosuppressive activities. Researchers have developed sphingomyelin nanosystems (SNs) loaded with anakinra (ANK), a recombinant IL-1 receptor antagonist, to inhibit pro-tumor inflammation in pancreatic cancer. The study found that ANK-SNs were effective in inhibiting the release of pro-tumor cytokines and IL-17 secretion by Th17 cells, potentially reducing the effective dose of the drug and its toxic effects. This research provides insights into potential therapeutic strategies for pancreatic cancer. [Extracted from the article]